SPL028

Overview

SPL028, or SPL-028, also known as α,α-dideutero-N,N-dimethyltryptamine (D₂-DMT), is a psychedelic drug of the tryptamine family which is under development for the treatment of depressive disorders. It is the analogue of dimethyltryptamine (DMT) in which the α carbon has been dideuterated. SPL028's route of administration is intravenous injection or intramuscular injection.[1–6] WP

Drug class

Serotonin receptor modulator Serotonergic psychedelic Hallucinogen WP

From the Wikipedia article's infobox.

Pharmacology

Pharmacology

SPL028 shows similar pharmacodynamics as DMT in vitro. Relatedly, SPL028 generalized with DMT in rodent drug discrimination tests. On the other hand, SPL028 differs from DMT in terms of pharmacokinetics; it is more resistant to metabolism and shows a prolonged duration. In a phase 1 clinical trial, SPL-028 by intramuscular injection produced robust psychedelic effects of short duration in humans.[1][5][7][8] WP

Research

Research

SPL028 was originated by Small Pharma and is under development by Cybin. Small Pharma was acquired by Cybin in 2023. As of February 2024, SPL028 is in phase 1 clinical trials.[3][9] WP

Chemistry

Formula

C12H16N2 PC

Molar mass (g/mol)

190.28 PC

IUPAC name (computed by PubChem)

1,1-dideuterio-2-(1H-indol-3-yl)-N,N-dimethylethanamine PC

SMILES

[2H]C([2H])(CC1=CNC2=CC=CC=C21)N(C)C PC

InChIKey

DMULVCHRPCFFGV-MGVXTIMCSA-N PC

PubChem CID

10241628

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Layzell M, Rands P, Good M, Joel Z, Cousins R, Benway T, James E, Routledge C. Discovery and In Vitro Characterization of SPL028: Deuterated N, N -Dimethyltryptamine. ACS Medicinal Chemistry Letters. 14 September 2023. doi:10.1021/acsmedchemlett.3c00143 · PMID 37736183 · PMC10510671
2. Journal / agency Kargbo RB. Application of Deuterated N, N -Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological Disorders. ACS Medicinal Chemistry Letters. 8 September 2022. doi:10.1021/acsmedchemlett.2c00354 · PMID 36105328 · PMC9465894
3. Journal / agency SPL 028. 16 February 2024
4. Other Delving into the Latest Updates on SPL-028 with Synapse. 14 June 2025
5. Journal / agency Good M, Cheetham S, Davis I. The International BNA 2023 Festival of Neuroscience: Preclinical characterisation of SPL028: a deuterated derivative of N,N-dimethyltryptamine, developing a treatment for mental health disorders. Brain and Neuroscience Advances. 2023. doi:10.1177/23982128231180246 · PMC10236260
6. Other Marino D. First Subject Dosed in Small Pharma's First-in-Human Phase 1 Clinical Trial. 15 February 2023
7. Other Good M, Joel Z, Cheetham S, Davis I, Rowley H, James E, Benway T, Routledge C. In vivo characterisation of SPL028: a deuterated derivative of N,N-dimethyltryptamine, developing a treatment for mental health disorders. April 2023
8. Other Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028. 5 April 2024
9. Other Alpha P. Cybin Set to Acquire British DMT Drug Developer Small Pharma. 28 August 2023

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.